Scilex (SCLXW) Stock: Why It Fell
Updated Oct 23, 6:05 AM ET · latest trade in feed Oct 22, 4:00 PM ET (Finnhub)
Updated Oct 22, 2026, 4:00 PM ET · closing price
- Latest 8-K (Sep 29, 2026): a material agreement (SEC)
- Latest session (Thu Oct 22): $0.05, −$0.01 (-24.83%), volume 21.3x its 50-day average.
- Earnings: latest quarter in SEC XBRL filings (ended Jun 30, 2026): diluted EPS $-16.65; revenue $7.6M, -22.8% year over year. Sources: SEC EDGAR XBRL.
Sector peers moving today (Pharma & Biotech):AVTX -39.23%KRRO +29.71%BHVN +25.02%MRNA -17.57%MLTX +15.87%
- Closed at $0.05, -24.83% vs the prior close of $0.06.
- Volume 5.38K shares, 21.3x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Revolution Medicines (RVMD)
SCLXW slides 24.8% to $0.05 on 21.3x normal volume. Closed at $0.05, -24.83% vs the prior close of $0.06. Day range $0.05–$0.05, opened at $0.17.
Why Did SCLXW Stock Move Today?
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Last 5 sessions at a glance, then today's full note.
| Session | Close | Change | Volume vs 50-day avg | What the data shows |
|---|---|---|---|---|
| Oct 22, 2026 | $0.05 | -24.83% | — | SCLXW slides 24.8% to $0.05 on 21.3x normal volume |
Oct 22, 2026 — SCLXW slides 24.8% to $0.05 on 21.3x normal volume
- Closed at $0.05, -24.83% vs the prior close of $0.06. Day range $0.05–$0.05, opened at $0.17.
- Volume was 5.38K shares, 21.3x its 50-day average of 253 — unusually heavy trading.
- 52-week range $0.05–$0.06; today's close sits at 0% of that range, 24.8% below the 52-week high.
Data-Driven Bull Case vs. Bear Case + Sector Peer Comparison Table
Points below restate what SEC filings and price data show. They are facts, not a recommendation.
- No clear positive signal in the price trend, filings or insider data right now.
- Annual revenue fell 46.5% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $374.05M.
- Insider selling outweighs buying: 12 sales vs 0 open-market buys among the 12 most recent reported insider trades (Form 4, last 12 months).
- Share count up 22.1% in a year (dilution).
- High volatility: average daily move of 24.8% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
Sector peers · Biological Products, (No Diagnostic Substances)
| Ticker | Company | Last price | Day | Below 52w high | Avg $ volume (20d) |
|---|---|---|---|---|---|
| SCLXW | Scilex | $0.05 | -24.83% | 24.8% | $129 |
| MRNA | Moderna | $202.63 | -17.57% | 20.4% | $4.09B |
| AMGN | Amgen | $447.28 | +2.04% | 0.8% | $1.16B |
| GILD | Gilead Sciences | $157.19 | +2.36% | 2.1% | $862.43M |
| TWST | Twist Bioscience | $135.47 | -9.16% | 38.3% | $525.87M |
| ARGX | Argenx Se | $875.76 | -1.61% | 18.4% | $440.37M |
| RVMD | Revolution Medicines | $187.69 | -3.39% | 16.3% | $414.31M |
| KOD | Kodiak Sciences | $85.78 | -2.21% | 17.5% | $352.79M |
| BIIB | Biogen | $253.84 | +5.34% | 0.2% | $299.48M |
SCLXW Earnings Date & EPS History
Diluted EPS by fiscal quarter, from Scilex's 10-Q/10-K filings (SEC XBRL).
| Quarter ended | Diluted EPS |
|---|---|
| Jun 30, 2026 | $-16.65 |
| Mar 31, 2026 | $-6.28 |
| Sep 30, 2025 | $-22.17 |
| Jun 30, 2025 | $-7.42 |
| Mar 31, 2025 | $-2.26 |
| Sep 30, 2024 | $-0.58 |
| Jun 30, 2024 | $-7.67 |
| Mar 31, 2024 | $-8.33 |
SCLXW Revenue, Net Income, Cash & Debt
- Revenue (quarter ended Jun 30, 2026): $7.64M
- Net income (quarter ended Jun 30, 2026): $-114.99M
- Cash & equivalents (as of Jun 30, 2026): $566.00K
- Long-term debt (as of Dec 31, 2022): $0
SCLXW Insider Buying & Form 4 Sales
In the last 12 months, SEC Form 4 filings show 0 open-market insider purchases and 12 sales of SCLXW (latest: Holding Co Scilex sold 9,657,300 shares on Dec 30, 2025). Full list in the insider table below.
SCLXW 52-Week High & Low
SCLXW's 52-week range is $0.05 to $0.06. At $0.05 it is 24.8% below the 52-week high and 0.0% above the 52-week low.
SCLXW Valuation: P/E, P/S, P/B, Margins & Cash vs Debt
Computed from Scilex's SEC XBRL filings and the latest price. A ratio is left out when its denominator is zero or negative.
| Measure | Value | How it is calculated |
|---|---|---|
| Market value | $383.03K | price $0.05 × 8.49M shares (Aug 10, 2026) |
| P/S | 0.01 | market value ÷ revenue $30.25M (FY to Dec 31, 2025) |
| Operating margin | -1143.7% | FY to Dec 31, 2025 |
| Net margin | -1236.4% | FY to Dec 31, 2025 |
| Free cash flow | $3.68M | operating cash flow $3.82M − capex $133.00K (FY to Dec 31, 2025) |
| Cash & equivalents | $566.00K | Jun 30, 2026 |
| Long-term debt | $0 | Dec 31, 2022 |
| Net cash (cash − debt) | $566.00K | from the two lines above |
SCLXW 5%+ Holders: Schedule 13D / 13G Filings
Filings by investors reporting a stake of 5% or more (13D = active, 13G = passive), newest first, from SEC EDGAR:
- SCHEDULE 13D/A filed Aug 24, 2026
- SCHEDULE 13D/A filed Jul 7, 2026
- SCHEDULE 13D/A filed Jun 26, 2026
- SCHEDULE 13G/A filed Feb 13, 2026
- SCHEDULE 13D/A filed Jan 14, 2026
- SCHEDULE 13D/A filed Jan 8, 2026
Latest SCLXW SEC 8-K & 10-Q Filings
Every SEC filing by or about SCLXW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 24, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $7.64M (prior year $9.90M) (-22.8% vs Jun 30, 2025)
- Net income: -$114.99M (prior year -$44.05M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$16.65 (prior year -$7.42) (loss widened vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jul 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
Jul 7, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 30, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Jun 26, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SCLXW
- Last results release: Oct 8, 2024 (8-K Item 2.02). Previous ones: Aug 1, 2024, Jul 1, 2024, Apr 16, 2024. Based on that rhythm, the next report is likely around Jan 7, 2025 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 24.83% (largest 24.8%). That is a volatile stock.
- Liquidity: about 2.81K shares (≈$127) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.05 vs a range of $0.05–$0.06 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 12 sales; latest: Holding Co Scilex sold 9,657,300 shares on Dec 30, 2025.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 14, 2026; 8-K Aug 12, 2026.
- Share count: 8.49M shares outstanding (Aug 10, 2026), +22.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SCLXW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | 0.17 | 0.05 | 0.05 | 0.05 | 5.38K |
| Oct 13, 2026 | 0.17 | 0.06 | 0.06 | 0.06 | 253 |
About Scilex
Scilex (SCLXW) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in PALO ALTO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1820190.
SCLXW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jay Chun | Director | Oct 9, 2025 |
| Dorman Followwill | Director | Oct 9, 2025 |
| Henry Ji | Exec Chair, CEO and President | Apr 20, 2026 |
| Stephen Hoi Ma | CFO, COO and Secretary | Apr 20, 2026 |
| Yue Alexander Wu | Director | Oct 9, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Henry Ji | Exec Chair, CEO and President | Apr 20, 2026 |
| Stephen Hoi Ma | CFO, COO and Secretary | Apr 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 30, 2025 | Holding Co Scilex | Sale | 9,657,300 | $0.54 |
| Dec 30, 2025 | Holding Co Scilex | Sale | 9,657,300 | $0.54 |
| Dec 30, 2025 | Holding Co Scilex | Sale | 9,657,300 | $0.54 |
| Dec 30, 2025 | Holding Co Scilex | Sale | 9,657,300 | $0.54 |
| Dec 29, 2025 | Holding Co Scilex | Sale | 7,310,984 | $0.66 |
| Dec 29, 2025 | Holding Co Scilex | Sale | 7,310,984 | $0.66 |
| Dec 29, 2025 | Holding Co Scilex | Sale | 7,310,984 | $0.66 |
| Dec 29, 2025 | Holding Co Scilex | Sale | 7,310,984 | $0.66 |
| Dec 26, 2025 | Holding Co Scilex | Sale | 3,689,016 | $0.75 |
| Dec 26, 2025 | Holding Co Scilex | Sale | 3,689,016 | $0.75 |
| Dec 26, 2025 | Holding Co Scilex | Sale | 3,689,016 | $0.75 |
| Dec 26, 2025 | Holding Co Scilex | Sale | 3,689,016 | $0.75 |
SCLXW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $30.25M | $-374.05M | -36.48 | $3.82M |
| Dec 31, 2024 | $56.59M | $-72.81M | -8.05 | $19.35M |
| Dec 31, 2023 | $46.74M | $-114.33M | -1.28 | $-20.71M |
| Dec 31, 2022 | $38.03M | $-23.36M | -0.17 | $-21.26M |
| Dec 31, 2021 | $31.32M | $-88.42M | -0.67 | $-28.66M |
Latest balance sheet: total assets $253.56M, total liabilities $564.05M, cash $566.00K (as of Jun 30, 2026).
SCLXW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 8, 2024 | 8-K Item 2.02 (results) | — |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| Jul 1, 2024 | 8-K Item 2.02 (results) | — |
| Apr 16, 2024 | 8-K Item 2.02 (results) | — |
| Mar 5, 2024 | 8-K Item 2.02 (results) | — |
| Jan 2, 2024 | 8-K Item 2.02 (results) | — |
| Dec 1, 2023 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
| Oct 2, 2023 | 8-K Item 2.02 (results) | — |
| Sep 11, 2023 | 8-K Item 2.02 (results) | — |
| Jul 5, 2023 | 8-K Item 2.02 (results) | — |
| Jun 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Revolution Medicines (RVMD)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Space Exploration Technologies (SPCX)Meta Platforms (META)Tesla (TSLA)Apple (AAPL)Sandisk (SNDK)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on SCLXW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 22, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.